Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Standardized Chemical Allergen [EPC]
Stellaria Media, commonly known as chickweed, is utilized in clinical medicine primarily as a standardized allergenic extract for the diagnosis and treatment of Type I hypersensitivity. It belongs to the class of Standardized Chemical Allergens used in immunotherapy protocols.
Name
Stellaria Media
Raw Name
STELLARIA MEDIA
Category
Standardized Chemical Allergen [EPC]
Drug Count
21
Variant Count
29
Last Verified
February 17, 2026
About Stellaria Media
Stellaria Media, commonly known as chickweed, is utilized in clinical medicine primarily as a standardized allergenic extract for the diagnosis and treatment of Type I hypersensitivity. It belongs to the class of Standardized Chemical Allergens used in immunotherapy protocols.
Detailed information about Stellaria Media
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Stellaria Media.
Stellaria Media, widely recognized by its common name 'chickweed,' is a versatile botanical entity that occupies a specific niche in modern clinical pharmacology, particularly within the field of allergology and immunology. While historically utilized in various folk medicine traditions, its primary contemporary clinical application is as a Standardized Chemical Allergen [EPC], as well as a Non-Standardized Plant Allergenic Extract [EPC]. In the context of the United States Food and Drug Administration (FDA) regulatory framework, Stellaria Media extracts are categorized as biological products used for the 'in vivo' diagnosis of specific allergies or as therapeutic agents in subcutaneous immunotherapy (SCIT).
As a member of the Caryophyllaceae family, Stellaria Media contains a complex profile of proteins, saponins, and flavonoids. When processed into a clinical-grade extract, it is used by healthcare providers to identify patients who exhibit hypersensitivity to the pollens or proteins associated with this species. The drug class designation of 'Standardized Chemical Allergen' implies that the extract has been manufactured to maintain a specific level of biological potency, often measured in Bioequivalent Allergy Units (BAU) or Protein Nitrogen Units (PNU), ensuring consistency across different lots of the medication.
In the context of diagnostic use, Stellaria Media works by eliciting a localized Type I hypersensitivity reaction. When a small amount of the extract is introduced into the skin via prick or intradermal testing, it interacts with specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells and basophils. If the patient is sensitized, this interaction triggers the release of inflammatory mediators, such as histamine and leukotrienes, resulting in a visible 'wheal and flare' reaction. This allows the clinician to confirm the presence of an allergy to the plant.
For therapeutic purposes, Stellaria Media is used in allergen immunotherapy. The mechanism involves the repeated administration of increasing doses of the allergen to the patient. Over time, this process induces 'immunological tolerance.' At the cellular level, this is characterized by a shift from a Th2-dominated immune response (which promotes IgE production) to a Th1-dominated response. Additionally, it stimulates the production of regulatory T-cells (Tregs) and the secretion of 'blocking antibodies' (IgG4), which compete with IgE for allergen binding, thereby reducing the allergic symptoms upon subsequent natural exposure.
The pharmacokinetics of allergenic extracts like Stellaria Media differ significantly from traditional small-molecule drugs. Because these are biological proteins administered parenterally or topically, they do not follow standard CYP450 metabolism pathways.
Stellaria Media extracts have several specific clinical indications approved by various global health authorities, including the FDA:
Stellaria Media is available in several specialized preparations, primarily for clinical use:
> Important: Only your healthcare provider can determine if Stellaria Media is right for your specific condition. The use of allergenic extracts must be conducted under the supervision of a physician trained in the management of anaphylaxis.
Dosage for Stellaria Media allergenic extracts is highly individualized and must be determined by an allergist based on the patient's sensitivity level and clinical history. There is no 'one-size-fits-all' dose.
Stellaria Media extracts are used in children, but extreme caution is required. Pediatric dosing follows the same 'start low and go slow' principle used in adults. Clinical studies suggest that children as young as 5 years old can safely undergo immunotherapy, provided they are monitored closely. Doses are adjusted based on the child's systemic reaction history rather than weight-based formulas used for other medications.
No specific dose adjustments are typically required for renal impairment, as the proteins are metabolized proteolytically. However, patients with severe renal disease may be at higher risk if systemic reactions occur, as their physiological reserve to handle anaphylaxis may be lower.
No adjustments are necessary for hepatic impairment. The liver's CYP450 system is not involved in the clearance of these allergenic proteins.
Elderly patients (over 65) should be evaluated for cardiovascular stability before starting Stellaria Media immunotherapy. If an elderly patient is taking beta-blockers for hypertension, the use of this extract may be contraindicated (see Interactions).
Stellaria Media extracts for immunotherapy are administered via subcutaneous injection, usually in the posterior aspect of the upper arm.
If a dose in the immunotherapy schedule is missed, the next dose may need to be reduced to avoid a systemic reaction due to a loss of tolerance.
An overdose of Stellaria Media extract (either too high a concentration or too large a volume) typically manifests as a severe systemic allergic reaction or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency of administration without medical guidance.
The most frequent side effects associated with Stellaria Media extracts are localized to the site of administration. These are expected pharmacological responses to the allergen.
These reactions are more widespread but not necessarily life-threatening:
> Warning: Stop taking Stellaria Media and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis:
With prolonged use of Stellaria Media in immunotherapy (typically 3-5 years), the primary 'side effect' is the intended modulation of the immune system. However, some patients may develop 'delayed local reactions,' where swelling appears 6-12 hours after the injection. There is no evidence that long-term use of these extracts causes autoimmune diseases or malignancy. In rare cases, chronic local irritation can lead to small areas of subcutaneous fibrosis (scarring) at frequent injection sites.
While Stellaria Media specifically may not have an individual black box warning for every manufacturer, the entire class of Allergenic Extracts carries a general FDA-mandated warning regarding the risk of severe non-fatal and fatal systemic reactions.
Summary of Warning:
Report any unusual symptoms to your healthcare provider. Even a 'small' systemic reaction (like a few hives) can predict a much more severe reaction at the next dose.
Stellaria Media extracts are potent biological agents that must be handled with extreme care. They are not intended for self-administration by the patient at home unless specifically trained and authorized under a very strict protocol (which is rare for this specific extract). The primary safety concern is the unpredictable nature of allergic sensitivity, which can fluctuate based on the patient's current health, recent allergen exposure, and even the weather.
No specific FDA black box warning exists solely for the Stellaria Media plant species; however, it falls under the Class-Wide Black Box Warning for Allergenic Extracts. This warning emphasizes that these products are intended for use only by physicians experienced in administering allergenic extracts and that they can cause anaphylaxis. It also notes that the risk is higher in patients with high degrees of sensitivity or those receiving injections during peak pollen seasons.
Stellaria Media does not directly cause sedation. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction, their ability to drive will be severely impaired. It is generally advised to wait until the 30-minute observation period is over and the patient feels completely normal before they drive.
Alcohol consumption should be avoided for several hours before and after an injection. Alcohol can cause vasodilation and may increase the rate of allergen absorption or mask the early symptoms of an allergic reaction.
If a patient experiences a life-threatening reaction to Stellaria Media, the therapy is typically discontinued permanently. If the patient decides to stop therapy for other reasons, there is no 'withdrawal' syndrome, but the allergic symptoms that the therapy was treating will likely return over time as the immunological tolerance fades.
> Important: Discuss all your medical conditions with your healthcare provider before starting Stellaria Media.
Mechanism of Interaction: The primary mechanism for most interactions with Stellaria Media is pharmacodynamic. For instance, beta-blockers block the beta-adrenergic receptors that epinephrine needs to stimulate to reverse airway constriction and low blood pressure. This does not change the level of the drug in the blood, but it changes how the body responds to the drug's most dangerous side effect.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Stellaria Media extracts must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the physician:
Patients allergic to Stellaria Media may also show cross-reactivity to other members of the Caryophyllaceae family (such as Dianthus or Silene). There is also some documented cross-reactivity with certain weed pollens and profilin proteins found in various fruits and vegetables. This is known as Pollen-Food Allergy Syndrome (PFAS).
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Stellaria Media.
FDA Pregnancy Category C (for most allergenic extracts). There are no adequate and well-controlled studies in pregnant women.
It is not known whether the allergenic proteins in Stellaria Media are excreted in human milk. However, because these are large proteins that are likely degraded in the mother's lymphatic system, the risk to the nursing infant is considered minimal. The decision to continue immunotherapy while breastfeeding should be made based on the mother's clinical need for the treatment.
Stellaria Media is approved for use in the pediatric population, typically for children 5 years of age and older. The efficacy is similar to that in adults. Special care must be taken to ensure the child can communicate early symptoms of a systemic reaction (e.g., 'my throat feels funny' or 'my palms are itchy'). Long-term studies have shown that allergen immunotherapy in children may actually prevent the development of new sensitivities and reduce the risk of progressing from allergic rhinitis to asthma.
Elderly patients may be at higher risk for complications from Stellaria Media therapy.
No specific studies have been conducted in patients with renal impairment. However, since the clearance of the proteins is via local proteolysis and not primarily through glomerular filtration, the standard dosing protocol is generally followed. Caution is advised in patients on dialysis due to overall physiological fragility.
No dosage adjustments are required. The liver's metabolic capacity does not affect the potency or safety of Stellaria Media allergenic extracts.
> Important: Special populations require individualized medical assessment.
Stellaria Media extracts function as an immunomodulator. In a sensitized individual, the initial exposure to the extract's proteins (allergens) triggers a Type I hypersensitivity reaction mediated by IgE.
When used therapeutically in SCIT (Subcutaneous Immunotherapy), the mechanism involves:
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous) |
| Protein Binding | Minimal (Local uptake by APCs) |
| Half-life | Variable (Proteins degraded in hours; immune effect lasts years) |
| Tmax | 15-30 minutes for systemic absorption |
| Metabolism | Local Proteolysis |
| Excretion | Renal (as amino acid metabolites) |
Stellaria Media is classified as a Standardized Chemical Allergen [EPC]. It is grouped with other weed and herb extracts used in allergy medicine. It is distinct from antihistamines or corticosteroids because it modifies the underlying disease process rather than just masking the symptoms.
Medications containing this ingredient
Common questions about Stellaria Media
Stellaria Media, or chickweed, is primarily used in clinical settings as an allergenic extract for diagnosing and treating allergies. Doctors use it in skin prick tests to identify if a patient is allergic to the plant's pollen or proteins. If an allergy is confirmed, the extract is used in immunotherapy (allergy shots) to gradually desensitize the patient's immune system. This process helps reduce symptoms like sneezing, itchy eyes, and asthma caused by chickweed exposure. It is not used as a first-line treatment but rather for patients who do not respond well to standard allergy medications.
The most common side effects are localized reactions at the site of the injection or skin test. These include redness, itching, swelling, and a warm sensation that usually resolves within 24 to 48 hours. Some patients may also experience a 'late-phase' reaction where swelling appears several hours after the injection. While these local reactions are common, they are generally not dangerous. However, large local reactions should always be reported to your doctor as they may indicate a need to adjust your next dose.
It is strongly recommended that you avoid alcohol consumption on the days you receive a Stellaria Media injection. Alcohol can cause your blood vessels to dilate, which might speed up the absorption of the allergen into your bloodstream and increase the risk of a systemic reaction. Furthermore, alcohol can mask the early warning signs of anaphylaxis, such as flushing or dizziness, making it harder for you or your doctor to recognize an emergency. Always wait at least several hours after your injection before considering alcohol, and only if you feel completely well. Discuss your lifestyle habits with your allergist to ensure the safest treatment plan.
The safety of Stellaria Media during pregnancy is a complex issue that requires a detailed discussion with your healthcare provider. Generally, doctors do not start new immunotherapy treatments during pregnancy because of the risk of anaphylaxis, which can deprive the fetus of oxygen. However, if you are already on a stable maintenance dose and have not had any bad reactions, your doctor may choose to continue the treatment at that same dose. The goal is to avoid any reactions that would require emergency treatment. Always inform your allergist immediately if you become pregnant while receiving these injections.
When used for allergy immunotherapy, Stellaria Media is not an 'instant fix' and requires significant time to modify the immune system. Most patients begin to notice a reduction in their allergy symptoms within 3 to 6 months of starting the 'build-up' phase. However, the full benefits are typically not realized until the patient has been on a maintenance dose for 12 to 18 months. A complete course of treatment usually lasts 3 to 5 years to ensure long-lasting protection. If no improvement is seen after one year of maintenance therapy, your doctor may re-evaluate the treatment plan.
Yes, you can stop taking Stellaria Media injections suddenly without experiencing physical withdrawal symptoms like those seen with some other medications. However, stopping the treatment before the recommended 3-to-5-year course is finished often means that your allergy symptoms will eventually return. The 'tolerance' your immune system built up may fade over several months. If you need to stop treatment due to side effects or lifestyle changes, it is best to discuss this with your allergist. They can advise you on the likelihood of your symptoms returning and suggest alternative management strategies.
If you miss a dose of Stellaria Media, you should contact your allergist's office as soon as possible to reschedule. Do not simply wait for your next scheduled appointment, as the timing of these injections is crucial for maintaining safety and effectiveness. Depending on how many weeks have passed since your last injection, your doctor may need to reduce the dose for your next visit to prevent a reaction. Missing too many doses may require you to restart the build-up process from a lower concentration. Consistency is the key to successful and safe allergen immunotherapy.
There is no clinical evidence to suggest that Stellaria Media allergenic extracts cause weight gain. Unlike systemic corticosteroids, which are sometimes used to treat allergies and are well-known for causing weight changes, allergenic extracts work specifically on the immune system's T-cells and B-cells. The amount of protein and other components in each injection is microscopic and does not affect your metabolism or appetite. If you experience weight gain while on this treatment, it is likely due to other factors or medications, and you should discuss it with your primary care physician.
Stellaria Media can be taken with many medications, but there are some very important exceptions. You must tell your doctor if you are taking beta-blockers, ACE inhibitors, or MAO inhibitors, as these can make allergic reactions much more dangerous and harder to treat. Most standard allergy medications, like antihistamines or nasal sprays, can be continued during immunotherapy, though they should be stopped before diagnostic skin testing. Always provide your allergist with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you use. This helps prevent dangerous interactions and ensures your treatment is as safe as possible.
Stellaria Media is not available as a 'generic' in the way that tablets like ibuprofen are. Instead, it is produced by several different biological laboratories as a standardized or non-standardized extract. While different brands may exist, they are biological products that are not necessarily interchangeable. Your allergist will typically stick with one manufacturer's extract for your entire course of treatment to ensure the potency remains consistent. Because these are specialized biological products, they are usually handled and billed through your doctor's office rather than a traditional retail pharmacy.